<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">Preclinical studies indicate opioid-induced neuroimmune signaling alter the saliency of opioid reward and physical dependence (Narita et al. 
 <xref ref-type="bibr" rid="CR355">2006</xref>; Hutchinson et al. 
 <xref ref-type="bibr" rid="CR215">2008</xref>, 
 <xref ref-type="bibr" rid="CR216">2009</xref>). Direct injections of astrocyte-conditioned medium containing cytokines into the nucleus accumbens (NAc) increase morphine conditioned place preference (Narita et al. 
 <xref ref-type="bibr" rid="CR355">2006</xref>). Drugs reported to selectively attenuate glial inflammation block morphine conditioned place preference and attenuate symptoms of opioid withdrawal (Narita et al. 
 <xref ref-type="bibr" rid="CR355">2006</xref>; Hutchinson et al. 
 <xref ref-type="bibr" rid="CR216">2009</xref>; Liu et al. 
 <xref ref-type="bibr" rid="CR292">2010</xref>). μ (MOR), δ (DOR), and κ (KOR) opioid receptors are expressed by subsets of astrocytes and microglia (Stiene-Martin and Hauser 
 <xref ref-type="bibr" rid="CR484">1991</xref>; Eriksson et al. 
 <xref ref-type="bibr" rid="CR142">1992</xref>; Stiene-Martin et al. 
 <xref ref-type="bibr" rid="CR485">1993</xref>; Ruzicka et al. 
 <xref ref-type="bibr" rid="CR443">1995</xref>; Gurwell et al. 
 <xref ref-type="bibr" rid="CR196">1993</xref>; Hauser et al. 
 <xref ref-type="bibr" rid="CR205">1996</xref>; Turchan-Cholewo et al. 
 <xref ref-type="bibr" rid="CR514">2008</xref>; Maduna et al. 
 <xref ref-type="bibr" rid="CR300">2018</xref>) and are involved in opioid tolerance and dependence to varying degrees (Kieffer and Gaveriaux-Ruff 
 <xref ref-type="bibr" rid="CR236">2002</xref>; Berger and Whistler 
 <xref ref-type="bibr" rid="CR41">2010</xref>; Morgan and Christie 
 <xref ref-type="bibr" rid="CR346">2011</xref>). Despite some reports of morphine triggering immune activation via Toll-like receptor 4 (TLR4) (Terashvili et al. 
 <xref ref-type="bibr" rid="CR503">2008</xref>; Hutchinson et al. 
 <xref ref-type="bibr" rid="CR217">2010</xref>; Coller and Hutchinson 
 <xref ref-type="bibr" rid="CR101">2012</xref>; Hutchinson et al. 
 <xref ref-type="bibr" rid="CR218">2012</xref>; Theberge et al. 
 <xref ref-type="bibr" rid="CR504">2013</xref>; Lacagnina et al. 
 <xref ref-type="bibr" rid="CR266">2017</xref>) by binding to a myeloid differentiation protein-2 intermediary (Wang et al. 
 <xref ref-type="bibr" rid="CR536">2012</xref>), this is contrary to the typical actions of opiates, which by themselves (and in the absence of a priming event such as HIV co-exposure) tend to suppress immune function (Eisenstein 
 <xref ref-type="bibr" rid="CR129">2019</xref>). A vast majority of the immune, antinociceptive, and other physiological effects of opioids are mediated by opioid receptors per se and not TLR4 (Hu et al. 
 <xref ref-type="bibr" rid="CR212">2011</xref>; Fukagawa et al. 
 <xref ref-type="bibr" rid="CR166">2013</xref>; Stevens et al. 
 <xref ref-type="bibr" rid="CR483">2013</xref>; Mattioli et al. 
 <xref ref-type="bibr" rid="CR319">2014</xref>; Eisenstein 
 <xref ref-type="bibr" rid="CR129">2019</xref>).
</p>
